drugset / Trial / NCT01609179

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

NCT01609179

Completed 9 enrolled Infinity Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A treatment protocol that enables patients to have continued access to IPI-926.

Timeline

Start
2012-03
Primary completion
2012-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Patidegib Small molecule 60 mg Oral
Subject Patidegib Small molecule 90 mg Oral
Subject Patidegib Small molecule 100 mg Oral
Subject Patidegib Small molecule 110 mg Oral
Subject Patidegib Small molecule 130 mg Oral
Subject Patidegib Small molecule 160 mg Oral